<DOC>
	<DOCNO>NCT02365207</DOCNO>
	<brief_summary>Patients invasive bladder cancer give 3-6 treatment ( base treatment response ) BCG intravesically follow cystectomy .</brief_summary>
	<brief_title>Intravesical BCG Administration Patients With Invasive Bladder Cancer</brief_title>
	<detailed_description>Patients muscle invasive ( ≥T1 ) bladder cancer give 3-6 treatment ( base treatment response ) intravesical TICE® BCG . BCG attenuate , live culture preparation Bacillus Calmette Guerin ( BCG ) strain Mycobacterium bovis . After completion BCG treatment patient undergo cystectomy . A portion bladder tumor tissue lymph node collect research purpose cystectomy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1 . Have suspect know invasive ( ≥T1 ) bladder cancer 2 . Be able give inform consent 3 . Be age 18 old 4 . Not immunosuppressed state ( e.g . HIV+ , use chronic steroid &gt; 1 month ) 1 . Have noninvasive ( &lt; T1 ) bladder cancer 2 . Unable give inform consent 3 . &lt; 18 old 4 . Is immunosuppressed state ( e.g . HIV+ , use chronic steroid &gt; 1 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>